End-of-day quote
Korea S.E.
03:30:00 14/05/2024 am IST
|
5-day change
|
1st Jan Change
|
22,400
KRW
|
+0.22%
|
|
+1.13%
|
-12.84%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,05,918
|
3,31,408
|
4,93,057
|
3,12,699
|
2,93,298
|
Enterprise Value (EV)
1 |
2,63,738
|
3,93,406
|
5,34,072
|
3,80,243
|
3,93,599
|
P/E ratio
|
-2.23
x
|
-7.67
x
|
-359
x
|
162
x
|
-9.55
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
1.39
x
|
2.56
x
|
2.98
x
|
1.63
x
|
2.35
x
|
EV / Revenue
|
1.78
x
|
3.04
x
|
3.23
x
|
1.98
x
|
3.16
x
|
EV / EBITDA
|
-21.1
x
|
-30.7
x
|
34.3
x
|
34.3
x
|
-25.8
x
|
EV / FCF
|
-
|
-3,13,36,514
x
|
-2,06,83,735
x
|
-1,42,09,957
x
|
-2,54,33,657
x
|
FCF Yield
|
-
|
-0%
|
-0%
|
-0%
|
-0%
|
Price to Book
|
2.04
x
|
5.71
x
|
4.96
x
|
1.86
x
|
2.13
x
|
Nbr of stocks (in thousands)
|
11,408
|
11,408
|
11,400
|
11,412
|
11,412
|
Reference price
2 |
18,050
|
29,050
|
43,250
|
27,400
|
25,700
|
Announcement Date
|
17/03/21
|
17/03/21
|
16/03/22
|
20/03/23
|
20/03/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
1,48,541
|
1,29,413
|
1,65,485
|
1,92,402
|
1,24,639
|
EBITDA
1 |
-12,504
|
-12,806
|
15,549
|
11,096
|
-15,264
|
EBIT
1 |
-26,543
|
-25,835
|
4,249
|
1,629
|
-24,095
|
Operating Margin
|
-17.87%
|
-19.96%
|
2.57%
|
0.85%
|
-19.33%
|
Earnings before Tax (EBT)
1 |
-80,197
|
-43,195
|
-4,011
|
2,241
|
-33,598
|
Net income
1 |
-92,323
|
-43,195
|
-1,375
|
2,133
|
-30,726
|
Net margin
|
-62.15%
|
-33.38%
|
-0.83%
|
1.11%
|
-24.65%
|
EPS
2 |
-8,098
|
-3,789
|
-120.6
|
169.0
|
-2,692
|
Free Cash Flow
|
-
|
-12,554
|
-25,821
|
-26,759
|
-15,476
|
FCF margin
|
-
|
-9.7%
|
-15.6%
|
-13.91%
|
-12.42%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
17/03/21
|
17/03/21
|
16/03/22
|
20/03/23
|
20/03/24
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
57,820
|
61,998
|
41,015
|
67,545
|
1,00,301
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-4.624
x
|
-4.841
x
|
2.638
x
|
6.087
x
|
-6.571
x
|
Free Cash Flow
|
-
|
-12,554
|
-25,821
|
-26,759
|
-15,476
|
ROE (net income / shareholders' equity)
|
-
|
-54.3%
|
-1.75%
|
1.6%
|
-22%
|
ROA (Net income/ Total Assets)
|
-
|
-6.13%
|
1.1%
|
0.37%
|
-4.83%
|
Assets
1 |
-
|
7,04,400
|
-1,25,038
|
5,74,863
|
6,36,143
|
Book Value Per Share
2 |
8,861
|
5,084
|
8,720
|
14,697
|
12,063
|
Cash Flow per Share
2 |
519.0
|
1,316
|
2,439
|
558.0
|
663.0
|
Capex
1 |
30,779
|
2,743
|
4,413
|
6,305
|
10,144
|
Capex / Sales
|
20.72%
|
2.12%
|
2.67%
|
3.28%
|
8.14%
|
Announcement Date
|
17/03/21
|
17/03/21
|
16/03/22
|
20/03/23
|
20/03/24
|
|
1st Jan change
|
Capi.
|
---|
| -12.84% | 187M | | +31.64% | 588B | | -3.36% | 364B | | +19.29% | 326B | | +5.18% | 285B | | +15.38% | 239B | | +10.05% | 210B | | -6.91% | 200B | | +9.95% | 167B | | -0.52% | 161B |
Other Pharmaceuticals
|